CAMBRIDGE, Mass. & LUCERNE, Switzerland--(BUSINESS WIRE)--Jan. 9, 2006--Biogen Idec (NASDAQ: BIIB) and Fumapharm AG today announced that a Phase II study designed to evaluate the efficacy and safety of BG-12, an oral fumarate, in patients with relapsing-remitting multiple sclerosis (MS) met its primary endpoint. Treatment with BG-12 led to a statistically significant reduction in the total number of gadolinium-enhancing brain lesions as measured by MRI with six months of treatment versus placebo. This Phase II multi-center, double-blind, placebo-controlled study enrolled approximately 250 patients at sites in 10 countries in Europe.
